24/7 Market News Snapshot 25 February, 2025 – GT Biopharma Inc. Common Stock (NASDAQ:GTBP)

February 25, 2025

DENVER, Colo., 25 February, 2025 (247marketnews.com) – (NASDAQ:GTBP) are discussed in this article.
GT Biopharma Inc. (GTBP) is currently making waves in the market following a significant surge in its stock price, which has reached $2.779, marking an impressive rise of 36.90% from the previous close of $2.030. This increase is bolstered by a robust trading volume of nearly 2 million shares, reflecting notable investor interest and confidence in the company’s strategic direction and innovative therapies. Such momentum suggests a growing optimism surrounding GT Biopharma’s promising developments in the biopharmaceutical sector.

In a noteworthy strategic move, GT Biopharma has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1 (File No. 333-284032), initially submitted on December 23, 2024. This decision underscores the company’s intent to refine its financial strategies while maintaining its focus on advancing its proprietary TriKE® platform, designed to enhance the immune system’s natural ability to target and eradicate cancer cells.

The registration statement had not yet been declared effective by the SEC, and no securities were sold related to this offering. GT Biopharma’s innovative approach, particularly its exclusive global license agreement with the University of Minnesota, positions the company for significant advancements in developing therapies based on its TriKE® technology.

In light of these developments, GT Biopharma remains committed to transparency with its stakeholders, encouraging them to consider various inherent risks and uncertainties that could impact outcomes in the biopharmaceutical industry. The company is poised for continued advancements in cancer treatment solutions, reinforcing its mission to deliver transformative therapies to patients in need.

Related news for (GTBP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.